Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Premenopausal sleep quality predicts insomnia in postmenopausal women

25 Jun 2020

Sleep disturbance is prevalent during and after menopause, with women with anxiety and depression being at higher risk, a study suggests. Poor sleep status in the premenopausal period predicts is a strong predictor of insomnia at menopausal transition and post-menopause.

The longitudinal cohort study involved 458 women from an urban Chinese community. Researchers assessed the presence of insomnia symptoms (trouble falling asleep, waking up early), vasomotor symptoms, anxiety and depression using the Hospital Anxiety and Depression Scale, and menopausal stages.

Multivariable analysis revealed that the prevalence of trouble falling asleep was significantly higher in menopausal transition (p=0.029) and post-menopause (p<0.001) compared with that in pre-menopause. Likewise, the prevalence of early-morning awakenings also increased in menopausal transition (p=0.003) and post-menopause (p=0.011).

Trouble falling asleep showed a positive association with anxiety (p=0.022) and depression (p=0.005).

Finally, women who had insomnia in pre-menopause were at increased risk of having moderate-to-severe insomnia in menopausal transition (p=0.003) and post-menopause (p=0.047) compared with those who did not experience the sleep disorder.

The findings have important implications, given that the severity and duration of sleep difficulties are said to vary in women transitioning menopause. Some may have occasional poor nights of sleep, which, although bothersome, only have a transient effect on quality of life. On the other hand, the experience of chronic and severe sleep difficulties has been linked to greater and more prolonged impact on daytime functioning, quality of life, and health. [Nat Sci Sleep 2018;10:73-95]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.